A clinical study of dyslipidemia in patients of chronic kidney disease
Author(s): Gourav Garg, Sumit Pal Singh Chawla*, Sarabjot Kaur
Cardiovascular disease is a major cause of morbidity and mortality in patients with Chronic Kidney Disease (CKD). Patients with CKD exhibit significant alterations in lipoprotein metabolism, which in their most advanced form may result in the development of severe dyslipidemia which can lead to increased risk of cardiovascular complications. The K/DOQI (Kidney Disease Outcomes Quality Initiative) guidelines suggest that all CKD patients should therefore be evaluated for dyslipidemia. Hence this study was undertaken to know the prevalence of dyslipidemia in CKD patients and thereby assess the impending risk of cardiovascular morbidity in these patients. This study was carried out in 100 CKD patients and it was observed that the mean values of Triglycerides (TG), Total Cholesterol (TC), Low Density Lipoprotein Cholesterol (LDL-C), Very Low Density Lipoprotein Cholesterol (VLDL-C), TC/HDL, LDL/HDL were increased and High Density Lipoprotein Cholesterol (HDL-C) was decreased in the patients under study. There was also statistically significant increase in the values of TG, TC, VLDL-C and TC/HDL with the progression of the disease (stage of CKD). Early recognition of dyslipidemia in CKD patients and maintenance of desired lipid levels either through diet or lipid lowering drugs can be helpful in decreasing the risk of cardiovascular complications in these patients.
Share this article
International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.